Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Alunbrig Brigatinib NSCLC Do not reimburse Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Alvesco Ciclesonide asthma List Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amvuttra vutrisiran Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Active
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete
Apprilon Doxycycline monohydrate Rosacea Do not list Complete
Aptiom Eslicarbazepine acetate Epilepsy, partial-onset seizures List with criteria/condition Complete